Posted by Michael Wonder on 21 Dec 2021
FDA approves first injectable treatment for HIV pre-exposure prevention
20 December 2021 - Drug given every two months rather than daily pill is important tool in effort to end the HIV epidemic.
Today, the U.S. FDA approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV.
